- Home
- TGTX vs IFS Comparison
TGTX vs IFS Comparison
Compare TGTX & IFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- IFS
- Stock Information
- Founded
- TGTX 1993
- IFS 1897
- Country
- TGTX United States
- IFS Peru
- Employees
- TGTX N/A
- IFS N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- IFS Commercial Banks
- Sector
- TGTX Health Care
- IFS Finance
- Exchange
- TGTX Nasdaq
- IFS Nasdaq
- Market Cap
- TGTX 4.2B
- IFS 4.2B
- IPO Year
- TGTX 1995
- IFS 2019
- Fundamental
- Price
- TGTX $32.18
- IFS $41.81
- Analyst Decision
- TGTX Strong Buy
- IFS Buy
- Analyst Count
- TGTX 4
- IFS 1
- Target Price
- TGTX $42.50
- IFS $30.00
- AVG Volume (30 Days)
- TGTX 2.0M
- IFS 164.0K
- Earning Date
- TGTX 11-03-2025
- IFS 11-11-2025
- Dividend Yield
- TGTX N/A
- IFS 2.26%
- EPS Growth
- TGTX N/A
- IFS 112.04
- EPS
- TGTX 0.36
- IFS 4.72
- Revenue
- TGTX $454,069,000.00
- IFS $1,492,951,578.00
- Revenue This Year
- TGTX $82.58
- IFS N/A
- Revenue Next Year
- TGTX $44.99
- IFS $10.80
- P/E Ratio
- TGTX $89.78
- IFS $8.88
- Revenue Growth
- TGTX 30.96
- IFS 34.92
- 52 Week Low
- TGTX $21.16
- IFS $23.95
- 52 Week High
- TGTX $46.48
- IFS $42.21
- Technical
- Relative Strength Index (RSI)
- TGTX 57.80
- IFS 70.11
- Support Level
- TGTX $31.34
- IFS $40.47
- Resistance Level
- TGTX $32.57
- IFS $42.21
- Average True Range (ATR)
- TGTX 1.13
- IFS 0.76
- MACD
- TGTX 0.54
- IFS 0.12
- Stochastic Oscillator
- TGTX 76.10
- IFS 88.75
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About IFS Intercorp Financial Services Inc.
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.